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Abstract
Ambulatory blood pressure monitoring (ABPM) can be used to identify white coat hypertension 
and guide hypertensive treatment. We determined the percentage of ABPM claims submitted 
between 2007–2010 that were reimbursed. Among 1,970 Medicare beneficiaries with submitted 
claims, ABPM was reimbursed for 93.8% of claims that had an ICD-9 diagnosis code of 796.2 
(“elevated blood pressure reading without diagnosis of hypertension”) versus 28.5% of claims 
without this code. Among claims without an ICD-9 diagnosis code of 796.2 listed, those for the 
component (e.g., recording, scanning analysis, physician review, reporting) versus full ABPM 
procedures and performed by institutional versus non-institutional providers were each more than 
two times as likely to be successfully reimbursed. Of the claims reimbursed, the median payment 
was $52.01 (25–75th percentiles: $32.95–$64.98). In conclusion, educating providers on the 
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ABPM claims reimbursement process and evaluation of Medicare reimbursement may increase 
the appropriate use of ABPM and improve patient care.
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INTRODUCTION
In the United States (US), the diagnosis and management of hypertension are primarily 
guided by blood pressure (BP) readings obtained in the clinic setting [1, 2]. However, many 
persons exhibit a white coat effect, defined as having BP that is higher in the clinic versus 
out-of-clinic setting, or white coat hypertension (WCH), defined as having hypertension 
based on clinic measurements despite having non-elevated BP outside of the clinic setting 
[3]. WCH is estimated to be present in 15% to 25% of individuals with elevated clinic BP 
[4]. It is generally accepted that the risk of cardiovascular disease in patients with WCH is 
low compared with those whose clinic and ambulatory BPs are both elevated (i.e., sustained 
hypertension) [4]. Ambulatory BP monitoring (ABPM) is considered the “gold standard” for 
identifying WCH, and has been found to be a cost-effective method to avoid overuse of 
antihypertensive medications [5, 6].
In 2001, the US Centers for Medicaid and Medicare Services (CMS) approved 
reimbursement for ABPM for patients with suspected WCH [7]. Despite the high prevalence 
of WCH in individuals with elevated clinic BP, only 0.1% of Medicare beneficiaries had a 
claim submitted for ABPM between 2007 and 2010 (see accompanying Shimbo et al. JASH 
article in current issue). These findings suggest that ABPM is being underutilized in 
Medicare beneficiaries. Concerns about unreimbursed claims and low reimbursement 
amounts may be barriers to performing ABPM in Medicare beneficiaries. Identifying factors 
that are associated with the successful reimbursement of ABPM by CMS may encourage its 
more widespread use in clinical practice. We examined the percentage of Medicare ABPM 
claims submitted that were reimbursed and the factors associated with successful 
reimbursement. We also examined the amounts reimbursed to providers and the factors 
associated with higher reimbursement amounts.
METHODS
We conducted a study of Medicare beneficiaries using the 2006–2010 national 5% random 
sample from the CMS. Medicare is a US federal health insurance program administered by 
the CMS that covers individuals 65 years of age and older, on disability, or who have end-
stage renal disease. Coverage may be chosen on a fee-for-service basis or through contracts 
with managed care organizations (i.e., Part C coverage also known as Medicare Advantage). 
Medicare data used for the current analyses were derived from the beneficiary enrollment 
file and fee-for-service Parts A (inpatient), B (outpatient), and D (pharmacy) claims. These 
data sources provide Medicare claims and assessment data linked by beneficiary across the 
continuum of care. We excluded Medicare beneficiaries with coverage through Part C from 
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the current analysis, as claims are incomplete for these individuals. CMS and the 
Institutional Review Board at the University of Alabama at Birmingham approved the study.
ABPM procedures were identified from 2007–2010 claims submitted through Medicare Part 
B. ABPM claims from 2006 were not included, allowing for a 365 day “look back” 
preceding the ABPM index claim that was used to define covariates, including healthcare 
utilization and comorbidities, for Medicare beneficiaries. Claims included those with 
Healthcare Common Procedure Coding System (HCPCS) codes for the “full” ABPM 
procedure (HCPCS code 93784) or the recording, scanning analysis, physician review, and 
reporting components (HCPCS codes 93786, 93788, or 93790) (Table 1). Each beneficiary’s 
first ABPM claim was used as his/her “index” claim. As all ABPM components may not be 
performed on the same date, we created an ABPM “episode” for each participant. The 
ABPM episode consisted of all ABPM claims submitted within a 30 day period beginning 
with and including the index claim (Figure 1). Reimbursement amounts are listed on ABPM 
claims. We categorized beneficiaries by whether or not at least one of their ABPM claims in 
the episode period was reimbursed, defined as a CMS payment of over $0. Beneficiaries 
were required to have continuous full Medicare coverage (Medicare Parts A, B and D 
coverage) and to reside in the 50 US states or Washington DC for the entire 365 day look 
back period through the 30 day ABPM episode period. In order to have the sample represent 
the general population, we excluded beneficiaries who were < 65 years of age at the start of 
the 365 day look back period.
Covariates
A priori-selected covariates were used to characterize Medicare beneficiaries with ABPM 
claims. Demographics, defined using the Medicare beneficiary enrollment file, included age, 
gender, race/ethnicity grouped as non-Hispanic white or other, Medicare/Medicaid dual 
eligibility for the entire look back period as a measure of poverty, and urban/rural status as 
defined using Rural/Urban Commuting Area codes. Diabetes, coronary heart disease, and 
kidney disease were defined using claims during the look back period and previously 
published algorithms (Appendix 1). We also determined the number of outpatient visits for 
hypertension each beneficiary had during the look back period. This was defined by the 
number of separate days with an outpatient physician evaluation and management claim 
with an International Classification of Diseases, 9th revision (ICD-9) diagnosis code of 
401.x (i.e. “malignant, benign or unspecified essential hypertension”). The number of 
antihypertensive medication classes each beneficiary filled during the look back period was 
identified from the Medicare Part D file. Antihypertensive medication classes were defined 
as listed in the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7) guidelines [8] and were updated by two authors 
(D.S., S.O.) to include newer medications. We defined WCH by the ICD-9 diagnosis code 
of 796.2 (i.e. “elevated blood pressure reading without diagnosis of hypertension”). 
Beneficiaries were considered to have a history of WCH if an ICD-9 code of 796.2 was 
present on one or more claims during the look back period. A WCH diagnosis was 
considered to be made concurrent with a beneficiary’s ABPM claim if the diagnosis code of 
796.2 was listed on the claim. We also categorized beneficiaries by whether at least one 
ABPM claim was submitted by a cardiologist (specialty code “06”), an institutional provider 
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(e.g. hospital outpatient department, rural health clinic, or dialysis center) versus by non-
institutional providers (e.g. individual physician, clinical laboratory, or free-standing 
ambulatory surgery center)[9], and for a full procedure versus for component procedures.
Statistical Analyses
The percentage of beneficiaries with a reimbursed ABPM claim was calculated, overall and 
separately for beneficiaries with and without a WCH diagnosis code on their ABPM claim. 
Next, among those without a WCH diagnosis code on an ABPM claim, relative risks and 
95% confidence intervals (CIs) for having a reimbursed ABPM claim were calculated using 
Poisson regression models and sandwich estimators. Relative risks were calculated for the 
covariates described above in unadjusted models and in a model that included all of these 
covariates. Among those without a WCH diagnosis code on their ABPM claims, we 
calculated the ten most common diagnosis codes for claims that were reimbursed and, 
separately, for those that were not reimbursed. We did not perform these calculations in 
beneficiaries with a WCH diagnosis code on their ABPM claims, since only a small 
percentage of these were not reimbursed.
For beneficiaries whose ABPM claims were reimbursed, we calculated the total amounts 
reimbursed, as well as the amounts paid for the full ABPM procedure and for each 
component. Differences in amounts reimbursed for full ABPM procedure claims across 
levels of the a priori selected covariates were calculated using general linear models. 
Models were conducted unadjusted and in a model that included all of these covariates. All 
analyses were conducted using SAS version 9.3 (Cary, North Carolina).
RESULTS
Between 2007 and 2010, ABPM claims were submitted for 1,970 Medicare beneficiaries. 
Overall, 1,347 (68.4%) of the 1,970 Medicare beneficiaries had an ABPM claim reimbursed 
(Table 2). A WCH diagnosis was listed on 1,202 (61.0%) of ABPM claims. Claims were 
reimbursed for 1,128 (93.8%) of beneficiaries with a WCH diagnosis on their ABPM claim. 
In contrast, claims were reimbursed for only 219 (28.5%) of beneficiaries without a WCH 
diagnosis on their ABPM claim. Beneficiaries were more likely to have a WCH diagnosis on 
their ABPM claim if they had a history of WCH, a claim for the full ABPM procedure, or an 
ABPM claim submitted by a cardiologist or institutional provider. Additionally, 
beneficiaries with a WCH diagnosis on their ABPM claim had fewer outpatient visits for 
hypertension and were taking fewer classes of antihypertensive medication during the look 
back period, were less likely to have a history of diabetes, and were more likely to have an 
urban residence than those who did not have a WCH diagnosis on their claim.
Table 3 shows the proportion of beneficiaries with reimbursed ABPM claims. Claims for 
ABPM procedure components and claims filed by institutional providers were more likely to 
be reimbursed. Having a history of WCH was associated with a higher likelihood of a 
reimbursement in the overall population, but not among those without a WCH diagnosis 
code on their ABPM claims. Having a rural residence was associated with a lower likelihood 
of reimbursement in the overall population, but with a higher likelihood of reimbursement 
among those without a WCH diagnosis on their ABPM claims. Table 4 shows unadjusted 
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and multivariable adjusted relative risks for having a reimbursed ABPM claim for 
participants with a WCH code on their ABPM claim. Among beneficiaries without a WCH 
code on their ABPM claims, those who had only ABPM procedure component claims versus 
a full procedure claim or a claim filed by an institutional provider were more likely to have 
their ABPM claim reimbursed after multivariable adjustment. Among beneficiaries without 
a WCH diagnosis on their ABPM claims, more than 80% had ICD-9 diagnosis codes for 
essential hypertension listed on both reimbursed (Supplemental Tables 1) and unreimbursed 
claims (Supplemental Table 2). Other diagnoses were coded on fewer than 10% of these 
claims.
The median amount paid for each beneficiary’s ABPM claims was $52.01 (25th, 75th 
percentiles: $32.95, $64.98) (Figure 2). Among those with only component ABPM claims, 
the median amount paid for a beneficiary’s ABPM claims was $30.46 (25th, 75th percentiles: 
$16.87, $44.05) compared with $55.14 (25th, 75th percentiles: $44.93, $66.37) for a claim 
for the full procedure. Among reimbursed claims for the full ABPM procedure, those 
submitted with versus without a WCH diagnosis had a $6.22 (95% CI: $5.06, $7.39) higher 
reimbursement. Rural beneficiaries had a $5.67 (95% CI: $4.88, $6.47) lower 
reimbursement amount compared to urban beneficiaries (Supplemental Table 3). Average 
reimbursement amounts differed by less than $5 across levels of the other characteristics 
examined. After multivariable adjustment, full ABPM procedure claims submitted with a 
WCH diagnosis and by institutional providers received higher reimbursements, while rural 
beneficiaries received lower reimbursements than urban beneficiaries.
DISCUSSION
The results of this study indicate that ABPM procedures performed in Medicare 
beneficiaries are likely to be reimbursed by CMS if the ICD-9 diagnosis code of 796.2 is 
included in the claim. We also found that almost 30% of claims without a 796.2 diagnosis 
code were reimbursed. Among claims without a 796.2 diagnosis code, claims for procedure 
components versus for the full ABPM procedure and those submitted by an institutional 
provider versus a non-intuitional provider were more than twice as likely to be reimbursed. 
The median reimbursement amount for an ABPM procedure was less than $60.
Medicare ABPM claim processing instructions define suspected WCH as having (1) at least 
three visits with an office BP >140/90 mm Hg, (2) at least two documented SBP/DBP 
measurements taken out of the office which are <140/90 mm Hg, and (3) no evidence of 
end-organ damage [10]. To indicate that ABPM was performed due to suspected WCH, 
Medicare instructs that an ABPM claim should list the ICD-9 code of 796.2 for a diagnosis 
of an “elevated blood pressure reading without diagnosis of hypertension”. We found that 
over 90% of ABPM claims with the ICD-9 diagnosis code of 796.2 were reimbursed. 
However, in the current study, 62% of beneficiaries with this diagnosis code on their ABPM 
claim were taking antihypertensive medications. Additionally, adjusted models indicated 
that claims were reimbursed at a similar rate for beneficiaries taking and not taking 
antihypertensive medication. While several publications defined WCH as a condition that 
occurs only in untreated patients [4, 11], prior research indicates that it is also valuable to 
determine the presence of a white coat effect in treated patients [12–14]. Based on the 
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results of the current study, Medicare does not appear to mandate that the ICD-9 diagnosis 
code of 796.2 should be restricted to patients who are not on antihypertensive medications.
It is not clear why almost 30% of ABPM claims without an ICD-9 diagnosis code of 796.2 
were reimbursed. We found that essential hypertension diagnosis codes were common on 
both reimbursed and unreimbursed ABPM claims without the 796.2 diagnosis code. Among 
beneficiaries with an ABPM claim that did not contain a WCH diagnosis code, those 
submitted by institutional providers were more likely to be reimbursed. This finding is 
consistent with results of prior studies that have shown that larger, urban healthcare 
providers that are part of hospital systems are more likely to have extensive documentation 
processes, including health information technology systems and documentation 
improvement programs [15–17], that may lead to the submission of more complete claims 
with a higher likelihood of reimbursement [18, 19]. We did not have access to the 
supporting documentation for ABPM claims and, therefore, could not assess whether the 
completeness of documentation was a determinant of success in receiving reimbursement.
Low reimbursement amounts for ABPM in Medicare beneficiaries may discourage 
healthcare providers from purchasing an ABPM device and performing ABPM. The mean 
reimbursement for an ABPM procedure in the current analysis is lower than the average of 
$74 (95% CI: $72, $76) reported in a previous analysis of Medicare data [20]. Even this 
higher reimbursement amount does not approach the cost of the procedure [14]. ABPM 
procedures were reported to have provider costs of AU$133 to AU$140 (US$125 to US
$131) in Australia [21], and £326 (US$559) in Britain [22], These low reimbursement 
amounts may discourage providers from performing ABPM. However, both the 2013 
European Society of Hypertension Position Paper on ABPM and the 2011 British National 
Institute for Health and Clinical Excellence (NICE) hypertension management guideline 
synthesized the literature and concluded that ABPM provides a cost-effective approach for 
guiding the diagnosis of hypertension [6, 23].
Limited indications for ABPM reimbursement by Medicare may also discourage providers 
from performing a procedure. Suspected WCH is the only covered indication, and Medicare 
instructs providers that the need for repeated ABPM procedures should be “rare” [10]. 
However, repeated ABPM procedures carried out over time may be useful to guide the 
treatment of hypertension, since the white coat effect and prevalence of WCH increase with 
age [23–26]. Importantly, repeated ABPM measures may be used to separate true and white 
coat treatment-resistant hypertension, to identify the development of sustained hypertension 
among those with diagnosed WCH [27, 28], and to guide antihypertensive therapy to 
achieve target blood pressures while avoiding overtreatment [14, 23, 29]. In addition to 
WCH, ABPM accurately identifies masked hypertension, defined as the presence of elevated 
out-of-office despite non-elevated clinic BP. Masked hypertension has been shown to be 
associated with a cardiovascular risk similar to that of sustained hypertension [30]. ABPM 
also has the unique ability to identify a number of abnormal circadian BP patterns associated 
with increased cardiovascular risk (e.g., elevated nighttime BP, a non-dipping pattern, and 
an increased morning surge) [23].
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Our study has several strengths. We used national data on US adults 65 years of age and 
older from Medicare. The national reach of Medicare provides high generalizability of our 
study results to older US adults. Since the size of the white coat effect may increase as 
patients age [24, 26], adopting the widespread use of ABPM holds even more importance 
among Medicare beneficiaries. Our study also has limitations. As with all claims-based 
analyses, our results depend on the accuracy of claims to identify comorbid conditions and 
pharmacy fills. In addition, given the restricted conditions for which Medicare reimburses an 
ABPM procedure, many providers may perform ABPM procedures without submitting a 
claim.
Conclusions
The vast majority of ABPM procedures for Medicare beneficiaries with suspected WCH are 
reimbursed if the ICD-9 diagnosis code of 796.2 is included on the claim. However, 
reimbursement amounts are generally below the cost of the procedure. Given low 
reimbursement amounts and limited indications, coverage may be insufficient to encourage 
the widespread use of ABPM for identifying WCH and monitoring treated hypertension. 
These issues may be barriers to performing ABPM in Medicare. Educating providers on 
CMS instructions for reimbursement of ABPM and evaluation of the reimbursement 
amounts for ABPM by CMS may increase its appropriate use in older US adults.
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Appendix 1. Medicare claims algorithms used to define beneficiary 
comorbidities
History of diabetes mellitus [31]
Any one of the following:
a. At least 1 inpatient claim with discharge ICD-9 diagnoses (any position) of 250.xx, 
357.2, 362.0×, or 366.41
b. At least 2 carrier claim, carrier line or outpatient claims with ICD-9 diagnoses (any 
position) of 250.xx, 357.2, 362.0×, or 366.41, linked by CLAIM_ID to an 
ambulatory physician evaluation and management claim, with the 2 claims 
occurring at least 7 days apart
c. At least 1 prescription record for an oral antidiabetes medication or insulin fills
History of coronary heart disease [32]
Any one of the following:
a. myocardial infarction: ≥1 inpatient or physician evaluation or management 
outpatient claims containing ICD-9 diagnoses 410.x or 412.x
b. revascularization: ≥1 inpatient or outpatient claim containing ICD-9 procedure 
codes 00.66, 36.01–36.09 or 36.10–36.19, or CPT codes 92980–92996, 33510–
33536, or ≥1 inpatient or outpatient claim containing ICD-9 diagnosis codes 
V45.81 or V45.82
c. Other ischemic disease: ≥1 inpatient or physician evaluation or management 
outpatient claim with 411, 413, or 414 codes.
History of stroke [33]
Any one of the following:
a. At least 1 inpatient ICD-9 diagnosis (any position) of 430.xx, 431.xx, 433.x1, 
434.x1 or 436.x
b. At least 1 carrier claim, carrier line or outpatient claims with ICD-9 diagnoses (any 
position) of 430.xx, 431.xx, 433.x1, 434.x1 or 436.x, linked by CLAIM_ID to an 
ambulatory physician evaluation and management claim
c. At least 1 claim with ICD-9 diagnoses (any position) of 430.xx, 431.xx, 433.x1, 
434.x1 or 436.x in other file types (home health aide, durable medical equipment, 
hospice, skilled nursing facility)
History of chronic kidney disease [34]
Any one of the following:
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a. at least 1 inpatient claim with discharge ICD-9 kidney disease diagnoses: 016.0, 
095.4, 189.0, 189.9, 223.0, 236.91, 250.4, 271.4, 274.1, 283.11, 403.xx, 404.xx, 
440.1, 442.1, 447.3, 572.4, 580.xx–588.xx, 591, 642.1, 646.2, 753.12–753.17, 
753.19, 753.2, 794.4
b. at least 2 carrier claim, carrier line or outpatient claims with kidney disease ICD-9 
diagnoses above (any position), with the 2 claims occurring at least 7 days apart.
History of heart failure [32]
At least one inpatient or outpatient, or carrier line or claim (any position) linked by 
CLAIM_ID to an ambulatory physician evaluation and management claim with ICD-9 
diagnoses of 398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 404.03, 404.13, 
404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 
428.40, 428.41, 428.42, 428.43, or 428.9
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• Only 68% of Medicare claims for ambulatory blood pressure are reimbursed.
• Claims are likely to be reimbursed if the ICD-9 diagnosis code 796.2 is 
included.
• Less than 30% of claims without a 796.2 diagnosis code were reimbursed.
• The median reimbursement amount for an ABPM procedure was $52.01.
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Study design to examine the reimbursement of ambulatory blood pressure monitoring 
(ABPM) claims in Medicare
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Figure 2. Amount reimbursed for an ambulatory blood pressure monitoring (ABPM) claim, by 
beneficiary and by Healthcare Common Procedure Coding System (HCPCS) procedure code. 
Statistics do not include unreimbursed ABPM claims.
Boxes show 25th and 75th percentiles of ABPM claim reimbursement amounts. Solid lines in 
boxes show the median reimbursement amounts. Dotted lines show mean reimbursement 
amounts. Whiskers show 10th and 90th percentiles of ABPM claim reimbursement amounts.
“Full procedure” claims were obtained from HCPCS 93784, defined as “ABPM, utilizing a 
system such as magnetic tape and/or computer disk, for 24 hours or longer; including 
recording, scanning analysis, interpretation and report.”
“Procedure recording” claims were obtained from HCPCS 93786, defined as “ABPM, 
utilizing a system such as magnetic tape and/or computer disk, for 24 hours or longer; 
recording only.”
“Scan, analysis and report” claims were obtained from HCPCS 93788, defined as “ABPM, 
utilizing a system such as magnetic tape and/or computer disk, for 24 hours or longer; 
scanning analysis with report.”
“Physician review and report” claims were obtained from HCPCS 93790, defined as 
“ABPM, utilizing a system such as magnetic tape and/or computer disk, for 24 hours or 
longer; physician review with interpretation and report.
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Table 1
Healthcare Common Procedure Coding System (HCPCS) codes used to identify ambulatory blood pressure 
monitoring (ABPM) in Medicare claims.
HCPCS code Description
93784 ABPM, utilizing a system such as magnetic tape and/or
computer disk, for 24 hours or longer; including recording,
scanning analysis, interpretation and report.
93786 ABPM, utilizing a system such as magnetic tape and/or
computer disk, for 24 hours or longer; recording only
93788 ABPM, utilizing a system such as magnetic tape and/or
computer disk, for 24 hours or longer; scanning analysis with
report.
93790 ABPM, utilizing a system such as magnetic tape and/or
computer disk, for 24 hours or longer; physician review with
interpretation and report.
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Table 2
Characteristics of Medicare beneficiaries in the 2007–2010 5% sample, overall and by the presence of a white 
coat hypertension (WCH) diagnosis on an ambulatory blood pressure monitoring (ABPM) claim.




(n=1970) No (n=768) Yes (n=1202) p-value
Reimbursed ABPM claim
   No 623 (31.6%) 549 (71.5%) 74 (6.2%) <.001
   Yes 1347 (68.4%) 219 (28.5%) 1128 (93.8%)
History of WCH
   No 1755 (89.1%) 730 (95.1%) 1025 (85.3%) <.001
   Yes 215 (10.9%) 38 (4.9%) 177 (14.7%)
ABPM procedure claim type†
   Full procedure 1546 (78.5%) 573 (74.6%) 973 (80.9%) 0.001
   Components 424 (21.5%) 195 (25.4%) 229 (19.1%)
ABPM claim filed by cardiologist
   No 1102 (55.9%) 461 (60.0%) 641 (53.3%) 0.004
   Yes 868 (44.1%) 307 (40.0%) 561 (46.7%)
ABPM claim filed by an
institutional provider††
<.001
   No 1676 (85.1%) 1061 (88.3%) 615 (80.1%)
   Yes 294 (14.9%) 141 (11.7%) 153 (19.9%)
Number of hypertension diagnoses
before ABPM claims
   0 230 (11.7%) 73 (9.5%) 157 (13.1%) 0.034
   1 to 5 1064 (54.0%) 415 (54.0%) 649 (54.0%)
   6 or more 676 (34.3%) 280 (36.5%) 396 (32.9%)
Number of antihypertensive
medication classes filled before
ABPM claims
   0 258 (13.1%) 68 (8.9%) 190 (15.8%) <.001
   1 or 2 708 (35.9%) 278 (36.2%) 430 (35.8%)
   3 or more 1004 (51.0%) 422 (54.9%) 582 (48.4%)
History of diabetes
   No 1479 (75.1%) 558 (72.7%) 921 (76.6%) 0.047
   Yes 491 (24.9%) 210 (27.3%) 281 (23.4%)
History of coronary heart disease
   No 1148 (58.3%) 458 (59.6%) 690 (57.4%) 0.327
   Yes 822 (41.7%) 310 (40.4%) 512 (42.6%)
History of kidney disease
   No 1626 (82.5%) 624 (81.3%) 1002 (83.4%) 0.229
   Yes 344 (17.5%) 144 (18.8%) 200 (16.6%)
Age, years 0.719
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(n=1970) No (n=768) Yes (n=1202) p-value
   65 to 74 908 (46.1%) 346 (45.1%) 562 (46.8%)
   75 to 84 816 (41.4%) 322 (41.9%) 494 (41.1%)
   85 and above 246 (12.5%) 100 (13.0%) 146 (12.1%)
Gender
   Female 1361 (69.1%) 518 (67.4%) 843 (70.1%) 0.209
   Male 609 (30.9%) 250 (32.6%) 359 (29.9%)
Race/ethnicity
   Non-Hispanic white 1758 (89.2%) 683 (88.9%) 1075 (89.4%) 0.726
   Other 212 (10.8%) 85 (11.1%) 127 (10.6%)
Medicare/Medicaid dual eligibility
   No 1666 (84.6%) 647 (84.2%) 1019 (84.8%) 0.751
   Yes 304 (15.4%) 121 (15.8%) 183 (15.2%)
Rural/urban residence
   Urban 1380 (70.1%) 485 (63.2%) 895 (74.5%) <.001
   Rural 590 (29.9%) 283 (36.8%) 307 (25.5%)
A WCH diagnosis is defined as ICD-9 code 796.2 (“Elevated blood pressure reading without diagnosis of hypertension”)
†
The full ABPM procedure is defined as an ABPM claim with Healthcare Common Procedure Coding System (HCPCS) code 93784, described as 
“ABPM, utilizing a system such as magnetic tape and/or computer disk, for 24 hours or longer; including recording, scanning analysis, 
interpretation and report.” Other HCPCS codes (93786, 93788, and 93790) are for individual ABPM procedure components.
††Claims filed by an institutional provider are defined as those in the outpatient file. Claims filed by a non-institutional provider are defined as 
those in the carrier file.
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Table 4
Multivariable adjusted relative risks for a reimbursed ambulatory blood pressure monitoring (ABPM) claim 
associated with Medicare beneficiary characteristics among those without a claim listing a white coat 





   No 1 (reference) 1 (reference)
   Yes 1.41 (0.94, 2.13) 1.37 (0.99, 1.90)
ABPM procedure claim type†
   Full procedure 1 (reference) 1 (reference)
   Components 4.13 (3.34, 5.12) 2.05 (1.45, 2.88)
ABPM claim filed by cardiologist
   No 1 (reference) 1 (reference)
   Yes 0.81 (0.64, 1.03) 0.94 (0.77, 1.15)
ABPM claim filed by an institutional provider††
   No 1 (reference) 1 (reference)
   Yes 4.53 (3.72, 5.52) 2.47 (1.79, 3.42)
Number of hypertension diagnoses before
ABPM claims
   0 1 (reference) 1 (reference)
   1 to 5 1.11 (0.73, 1.68) 1.07 (0.76, 1.52)
   6 or more 1.10 (0.71, 1.69) 0.97 (0.67, 1.42)
Number of antihypertensive medication classes
filled before ABPM claims
   0 1 (reference) 1 (reference)
   1 or 2 1.43 (0.87, 2.36) 1.21 (0.78, 1.87)
   3 or more 1.42 (0.87, 2.31) 1.35 (0.87, 2.10)
History of diabetes
   No 1 (reference) 1 (reference)
   Yes 1.15 (0.90, 1.46) 1.16 (0.92, 1.45)
History of coronary heart disease
   No 1 (reference) 1 (reference)
   Yes 0.80 (0.63, 1.02) 0.83 (0.67, 1.03)
History of kidney disease
   No 1 (reference) 1 (reference)
   Yes 1.06 (0.80, 1.40) 0.97 (0.76, 1.23)
Age, years
   65 to 74 1 (reference) 1 (reference)
   75 to 84 1.07 (0.84, 1.37) 1.04 (0.84, 1.28)
   85 and above 1.06 (0.74, 1.50) 0.99 (0.74, 1.33)
Gender

















   Female 1 (reference) 1 (reference)
   Male 0.95 (0.75, 1.21) 0.99 (0.80, 1.23)
Race/ethnicity
   Non-Hispanic white 1 (reference) 1 (reference)
   Other 0.76 (0.51, 1.15) 0.94 (0.64, 1.36)
Medicare/Medicaid dual eligibility
   No 1 (reference) 1 (reference)
   Yes 0.78 (0.55, 1.11) 0.81 (0.60, 1.10)
Rural/urban residence
   Urban 1 (reference) 1 (reference)
   Rural 1.36 (1.09, 1.70) 1.09 (0.89, 1.33)
A WCH diagnosis is defined as ICD-9 code 796.2 (“Elevated blood pressure reading without diagnosis of hypertension”)
†
The full ABPM procedure is defined as an ABPM claim with Healthcare Common Procedure Coding System (HCPCS) code 93784, described as 
“ABPM, utilizing a system such as magnetic tape and/or computer disk, for 24 hours or longer; including recording, scanning analysis, 
interpretation and report.” Other HCPCS codes (93786, 93788, and 93790) are for individual ABPM procedure components.
††Claims filed by an institutional provider are defined as those in the outpatient file. Claims filed by a non-institutional provider are defined as 
those in the carrier file.
†††
Fully adjusted risk ratios are adjusted for all characteristics presented in the table.
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